[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100401313":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":50,"centralContacts":54,"locations":63,"responsibleParty":84,"collaborators":86,"id":90,"slug":44,"hasResults":91,"nctId":92,"briefTitle":93,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":96,"sex":97,"minAge":98,"maxAge":99,"enrollmentInfo":100,"targetDuration":44,"studyType":103,"phases":104,"briefSummary":106,"conditions":107,"keywords":44,"overallStatus":66,"whyStopped":44,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":121},{"fullName":5,"class":6},"Johns Hopkins University","OTHER",[8,16,20,24],{"label":9,"type":6,"description":10,"interventionNames":11},"Controls","Subjects in this group do not have any ocular pathology and are also not hypertensive. Some subjects in this arm will undergo retinal vascular reactivity assessments.",[12,13,14,15],"Device: Swept-Source (SS) OCT Angiography","Device: Spectral-Domain (SD) OCT Angiography","Device: Fundus Imaging","Device: Axial Length Measurement Device",{"label":17,"type":6,"description":18,"interventionNames":19},"Diabetics with and without Diabetic Retinopathy Only","Subjects in this group only have diabetes with or without diabetic retinopathy. Some subjects in this arm will undergo retinal vascular reactivity assessments.",[12,13,14,15],{"label":21,"type":6,"description":22,"interventionNames":23},"Hypertension Only","Subjects in this group only have hypertension with or without ocular pathology related to hypertension. Some subjects in this arm may undergo retinal vascular reactivity assessments.",[12,13,14,15],{"label":25,"type":6,"description":26,"interventionNames":27},"Diabetics w\u002F or w\u002Fo Diabetic Retinopathy & Hypertension","Subjects in this group have diabetes with or without diabetic retinopathy and hypertension with or without ocular pathology related to hypertension. Some subjects in this arm may undergo retinal vascular reactivity assessments.",[12,13,14,15],[29,36,41,45],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"DEVICE","Swept-Source (SS) OCT Angiography","Non-invasive, minimal risk, ocular imaging study",[9,25,17,21],[35],"SS-OCTA",{"type":30,"name":37,"description":32,"armGroupLabels":38,"otherNames":39},"Spectral-Domain (SD) OCT Angiography",[9,25,17,21],[40],"SD_OCTA",{"type":30,"name":42,"description":32,"armGroupLabels":43,"otherNames":44},"Fundus Imaging",[9,25,17,21],null,{"type":30,"name":46,"description":32,"armGroupLabels":47,"otherNames":48},"Axial Length Measurement Device",[9,25,17,21],[49],"Intraocular Lens (IOL) Master",[51],{"name":52,"affiliation":5,"role":53},"Amir Kashani, MD, MPH","PRINCIPAL_INVESTIGATOR",[55,60],{"name":56,"role":57,"phone":58,"phoneExt":44,"email":59},"Amir H Kashani, MD, PhD","CONTACT","410-502-2789","akashan1@jhmi.edu",{"name":61,"role":57,"phone":58,"phoneExt":44,"email":62},"Ana C Martinez, MPH","acollaz5@jhmi.edu",[64],{"facility":65,"status":66,"city":67,"state":68,"zip":69,"country":70,"cosmosGeoPoint":71,"geoPoint":76,"contacts":77},"Wilmer Eye Institute","RECRUITING","Baltimore","Maryland","21287","United States",{"type":72,"coordinates":73},"Point",[74,75],-76.61219,39.29038,{"lat":75,"lon":74},[78,81,83],{"name":79,"role":57,"phone":80,"phoneExt":44,"email":62},"Ana Collazo Martinez","410-502-5052",{"name":82,"role":57,"phone":44,"phoneExt":44,"email":44},"C",{"name":56,"role":53,"phone":44,"phoneExt":44,"email":44},{"type":85,"investigatorFullName":44,"investigatorTitle":44,"investigatorAffiliation":44,"oldNameTitle":44,"oldOrganization":44},"SPONSOR",[87],{"name":88,"class":89},"National Eye Institute (NEI)","NIH","100401313",false,"NCT04505618","Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease","OCTA-RVD","Exclusion Criteria:\n\n* Both subjects with diseases and controls:\n* Children (age\\\u003C18)\n* Pregnant females\n* Developmentally delayed subjects\n* Subjects unable to provide informed consent\n* Inability to cooperate with tests and study instructions\n* Images with motion artifact or signal strength \\\u003C 7\n* History of glaucoma\n* History of age-related macular degeneration\n* History of any visually significant eye disease\n* History of proliferative diabetic retinopathy\n* History of any inflammatory disease\n* History of heart disease\n* History of thyroid disease.\n* Additional criteria for controls:\n* History of any type of Diabetes Mellitus\n* History of any type of Hypertension",true,"ALL","18 Years","99 Years",{"count":101,"type":102},1050,"ESTIMATED","INTERVENTIONAL",[105],"NA","This study will perform a prospective, longitudinal analysis of clinical and imaging findings from normal controls and subjects with retinal vascular disease to better define the diagnostic imaging criteria that signify change in disease stage. This includes disease progression in early stages of disease or disease regression with appropriate standard-of-care treatment.",[108,109,110,111],"Diabetic Retinopathy","Retinal Vein Occlusion","Hypertension,Essential","Retinal Vascular Disorder","2026-06-15",{"date":114,"type":115},"2026-06-17","ACTUAL",{"date":117,"type":115},"2019-10-01",{"date":119,"type":102},"2027-09-01",{"name":5,"class":6},1]